#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 26, 2026 at 1:15 PM
#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
October 4, 2026 at 7:34 PM
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Our Phase 2a Alzheimer's trial (49 participants) showed laromestrocel significantly reduced neuroinflammation in brain regions like the hippocampus (p<0.001). Calming these damaging brain responses may help protect function.
New Analysis of Laromestrocel Phase 2a Data in Alzheimer's Disease Suggests Reduced Neuroinflammatio
Longeveron Inc. announced new data analysis from its Phase 2a clinical trial (CLEAR MIND study) for laromestrocel, a cell therapy for Alzheimer's disease. The analysis indicates that treatment with la
www.biospace.com
October 1, 2026 at 8:02 AM
Our Phase 2a Alzheimer's trial (49 participants) showed laromestrocel significantly reduced neuroinflammation in brain regions like the hippocampus (p<0.001). Calming these damaging brain responses may help protect function.
Longeveron’s Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome missed its primary endpoint. Further analyses and FDA discussions are planned.
#Biotech #Biotechnology #Trial
Disclaimer: This is NOT a financial advice
#Biotech #Biotechnology #Trial
Disclaimer: This is NOT a financial advice
September 23, 2026 at 11:40 PM
Longeveron’s Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome missed its primary endpoint. Further analyses and FDA discussions are planned.
#Biotech #Biotechnology #Trial
Disclaimer: This is NOT a financial advice
#Biotech #Biotechnology #Trial
Disclaimer: This is NOT a financial advice
Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
September 18, 2026 at 7:05 AM
Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation #NeuroDegeneration 🧪🧠
https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
September 18, 2026 at 4:25 AM
Laromestrocel preserves brain volume and cognitive function in Alzheimers disease by inhibiting neuroinflammation https://www.medrxiv.org/content/10.64898/2026.09.16.26363132v1
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
September 17, 2026 at 3:56 PM
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
$LGVN's Phase 2b trial for laromestrocel in HLHS infants failed primary endpoint; no significant benefit seen at 12 months (p=0.83).
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 09/17/26
export-download.canva.com
September 17, 2026 at 12:40 PM
$LGVN's Phase 2b trial for laromestrocel in HLHS infants failed primary endpoint; no significant benefit seen at 12 months (p=0.83).
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
🚀 Zacks Small Cap Research - LGVN at a Major Inflection Point
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-at-a-major-inflection-point/
#LGVN #Lon#LGVNo#Longeveronr#Laromestrocel##Phase2b##ELPISIIp#HLHSt#HypoplasticLeftHeartz#PDCMr#AlzheimersDiseasei#AgingFrailty
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-at-a-major-inflection-point/
#LGVN #Lon#LGVNo#Longeveronr#Laromestrocel##Phase2b##ELPISIIp#HLHSt#HypoplasticLeftHeartz#PDCMr#AlzheimersDiseasei#AgingFrailty
August 14, 2026 at 8:49 AM
🚀 Zacks Small Cap Research - LGVN at a Major Inflection Point
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-at-a-major-inflection-point/
#LGVN #Lon#LGVNo#Longeveronr#Laromestrocel##Phase2b##ELPISIIp#HLHSt#HypoplasticLeftHeartz#PDCMr#AlzheimersDiseasei#AgingFrailty
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-at-a-major-inflection-point/
#LGVN #Lon#LGVNo#Longeveronr#Laromestrocel##Phase2b##ELPISIIp#HLHSt#HypoplasticLeftHeartz#PDCMr#AlzheimersDiseasei#AgingFrailty
#LGVN Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
https://www.stocktitan.net/news/LGVN/longeveron-announces-2026-second-quarter-financial-results-and-nzziw1bblc7y.html
https://www.stocktitan.net/news/LGVN/longeveron-announces-2026-second-quarter-financial-results-and-nzziw1bblc7y.html
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan-designated indication Longeveron selected as a Finalist and Milestone 2
www.stocktitan.net
August 12, 2026 at 8:05 PM
#LGVN Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
https://www.stocktitan.net/news/LGVN/longeveron-announces-2026-second-quarter-financial-results-and-nzziw1bblc7y.html
https://www.stocktitan.net/news/LGVN/longeveron-announces-2026-second-quarter-financial-results-and-nzziw1bblc7y.html
I'm still thinking about Longeveron's stem cell therapy. Clinical trials showed laromestrocel helped people with aging-related frailty walk further in 6 minutes. It's a finalist for XPRIZE Healthspan! Unexpected progress in mobility.
Longeveron's Stem Cell Therapy Laromestrocel Shows Clinical Benefit in Aging-related Frailty, Advanc
Longeveron Inc. has been named a finalist for the prestigious XPRIZE Healthspan competition, receiving a Milestone 2 Award. This recognition is due to published clinical trial results demonstrating th
www.globenewswire.com
August 11, 2026 at 8:03 PM
I'm still thinking about Longeveron's stem cell therapy. Clinical trials showed laromestrocel helped people with aging-related frailty walk further in 6 minutes. It's a finalist for XPRIZE Healthspan! Unexpected progress in mobility.
Stem cell therapy using your own bone marrow derived stem cells- this will be the future of medicine and not that non-sensical "stem cell therapy" using stem cells from other species or other weird stuff: www.sciencedirect.com/science/arti...
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Frailty, a syndrome that decreases healthspan in older individuals, lacks effective therapies. We conducted a randomized, dose-finding clinical trial …
www.sciencedirect.com
February 27, 2026 at 7:53 PM
Stem cell therapy using your own bone marrow derived stem cells- this will be the future of medicine and not that non-sensical "stem cell therapy" using stem cells from other species or other weird stuff: www.sciencedirect.com/science/arti...
$LGVN +13.86% [Longeveron's laromestrocel stem cell therapy IND approved by FDA for pediatric DCM, a life-threatening heart disease. Phase 2 trial H1 2026.] investors.longeveron.com/news/News/ne...
Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM)
Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trial Phase 2 clinical trial initiation anticipated in first half of 2026 Pediatric ...
investors.longeveron.com
July 8, 2025 at 4:49 PM
$LGVN +13.86% [Longeveron's laromestrocel stem cell therapy IND approved by FDA for pediatric DCM, a life-threatening heart disease. Phase 2 trial H1 2026.] investors.longeveron.com/news/News/ne...
Laromestrocel therapy showed safety and slowed cognitive decline and brain atrophy in mild Alzheimer's disease patients.
by Rash BG, Ramdas KN (...) Hare JM et 21 al. in Nat Med #MedSky
📖 read the article:
by Rash BG, Ramdas KN (...) Hare JM et 21 al. in Nat Med #MedSky
📖 read the article:
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial - Nature Medicine
Single and multiple intravenous infusions with laromestrocel, an allogeneic cell therapy, is safe in patients with mild AD and may reduce the impact of cognitive decline and brain atrophy within 9 months of treatment.
www.nature.com
March 19, 2025 at 6:38 PM
Laromestrocel therapy showed safety and slowed cognitive decline and brain atrophy in mild Alzheimer's disease patients.
by Rash BG, Ramdas KN (...) Hare JM et 21 al. in Nat Med #MedSky
📖 read the article:
by Rash BG, Ramdas KN (...) Hare JM et 21 al. in Nat Med #MedSky
📖 read the article:
Frailty used to be something we just accepted with age. Now a Phase 2 trial shows stem cell therapy (Laromestrocel) improved endurance & reduced frailty in older adults. Reversing aging markers? Quietly revolutionary.
Stem Cell Therapy for Frailty Just Crossed a Major Milestone
A recently published Phase 2b clinical trial demonstrated that a single intravenous dose of Laromestrocel, a mesenchymal stem cell therapy, significantly improved physical endurance and reduced frailt
www.lisatamati.com
March 4, 2026 at 2:00 PM
Frailty used to be something we just accepted with age. Now a Phase 2 trial shows stem cell therapy (Laromestrocel) improved endurance & reduced frailty in older adults. Reversing aging markers? Quietly revolutionary.
A phase 2a trial in the U.S. tested laromestrocel, a stem cell therapy, in 49 patients with mild Alzheimer’s.
It was safe and slowed brain atrophy by 48.4% at 39 weeks.
Cognitive function showed promising trends.
Larger trials are needed
www.nature.com/articles/s41...
It was safe and slowed brain atrophy by 48.4% at 39 weeks.
Cognitive function showed promising trends.
Larger trials are needed
www.nature.com/articles/s41...
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer’s disease: a randomized controlled phase 2a trial - Nature Medicine
Single and multiple intravenous infusions with laromestrocel, an allogeneic cell therapy, is safe in patients with mild AD and may reduce the impact of cognitive decline and brain atrophy within 9 mon...
www.nature.com
March 10, 2025 at 12:16 PM
A phase 2a trial in the U.S. tested laromestrocel, a stem cell therapy, in 49 patients with mild Alzheimer’s.
It was safe and slowed brain atrophy by 48.4% at 39 weeks.
Cognitive function showed promising trends.
Larger trials are needed
www.nature.com/articles/s41...
It was safe and slowed brain atrophy by 48.4% at 39 weeks.
Cognitive function showed promising trends.
Larger trials are needed
www.nature.com/articles/s41...
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty
www.cell.com/cell-stem-ce...
www.cell.com/cell-stem-ce...
March 9, 2026 at 3:09 PM
Randomized phase 2b dose-escalation trial of stem cell therapy with laromestrocel for aging frailty
Longeveron's Laromestrocel for Frailty: journal club on @cp-cellstemcell.bsky.social pub Data & Problematic Nature news Coverage ipscell.com/2026/03/long... #stemcells #stemcell @caulfieldtim.bsky.social
Longeveron's Laromestrocel for Frailty: Breaking Down Cell Stem Cell Data & Problematic Nature Coverage - The Niche
Biologist provides perspectives on new MSC frailty study published in Cell Stem Cell from Longeveron and provides background.
ipscell.com
March 4, 2026 at 6:38 PM
Longeveron's Laromestrocel for Frailty: journal club on @cp-cellstemcell.bsky.social pub Data & Problematic Nature news Coverage ipscell.com/2026/03/long... #stemcells #stemcell @caulfieldtim.bsky.social
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial
->Nature | #Disease #Health | More info from EcoSearch
->Nature | #Disease #Health | More info from EcoSearch
Allogeneic mesenchymal stem cell therapy with laromestrocel in mild Alzheimer's disease: a randomized controlled phase 2a trial
The CLEAR-MIND study entitled ‘Lomecel-B Effects on Alzheimer’s disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial’ (ClinicalTrials.gov registration: NCT05233774) was conducted using our trial protocol under US FDA IND no. 16524, which is available in the trial master file. Institutional...
www.nature.com
March 11, 2025 at 4:05 PM